Alprazolam

For high-incidence psychiatric disorders such as anxiety disorder and panic attacks, benzodiazepines are commonly used clinical treatment options. As an intermediate-acting preparation among them, alprazolam acts on the γ-aminobutyric acid receptors of the central nervous system to enhance the conduction effect of inhibitory neurotransmitters, which can rapidly relieve anxiety symptoms. It is also used to adjuvantly improve depressive symptoms accompanied by anxiety, exert sedative and hypnotic effects, and alleviate acute alcohol withdrawal reactions. Its applicable population covers adult patients with anxiety disorder and groups requiring short-term control of panic attacks. It has been clinically applied for more than 40 years and is one of the basic medications in the diagnosis and treatment pathway of psychiatric disorders.

The global market size of alprazolam preparations is stable at around 2.2 billion US dollars, and the annual sales in the domestic market exceed 1.5 billion yuan, with a compound annual growth rate of 3.8% in the past 3 years. Due to the early marketing time of this variety, generic drugs currently account for more than 95% of the domestic market. It has been included in the national centralized volume-based procurement, and the price of winning preparations has dropped by more than 80%. With the increase in the consultation rate of psychiatric disorders, the demand for upstream APIs continues to grow. Domestic API manufacturers are mainly pharmaceutical enterprises in East China and North China, and the overall supply pattern is relatively stable.

The original research enterprise of alprazolam is Pfizer, and the original research trade name is Xanax. The core compound patent in the United States expired in 1993. The main dosage form of the original research product is oral tablet, with three specifications including 0.25mg, 0.5mg and 1mg. It has been included in the FDA Reference Listed Drug Catalog, and is also included in China's *Catalog of Reference Listed Drugs for Chemical Drugs*. According to the domestic API registration platform, more than 20 enterprises have obtained A-status registration numbers for alprazolam APIs so far, there are more than 180 domestic preparation approvals, and the original research preparation has also been approved for marketing in China. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO provides a full set of impurity reference standards for alprazolam API, which can cover the needs of all links of drug development, quality research and consistency evaluation. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All reference standards comply with the regulatory requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet various quality control scenarios of pharmaceutical enterprises.